ADDvise receives order worth USD 1.3 million

20-09-2024   Regulatory press release

ADDvise Group’s subsidiary MRC Systems has received an order from Medisept. The company is a medical device manufacturer for the healthcare industry based in Oran, Algeria.

The order is worth approximately USD 1.3 million. The order involves design, paneling, and installation of a cleanroom and associated accessories for a new medical device manufacturing facility with approximately 700m2 of production area located in Oran, Algeria. Delivery of the order is scheduled to be completed during Q2 2025.
 

For further information, please contact:

Staffan Torstensson, CEO
+46 704 33 20 19
staffan.torstensson@addvisegroup.se

Important information

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on September 20, 2024 at 14:20 CEST.

About ADDvise Group

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Latest press releases

ADDvise publishes prospectus in connection with a rights issue

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…

Report from the extra ordinary general meeting in ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363-2115 (the "Company"), has held an extraordinary general meeting on 12 March 2025. The general meeting resolved to amend the articles of association, approve the board's resolution regarding a rights issue of shares of series A and series B, approve the board's resolution on a directed issue of warrants…

Year-end report 2024, January 1–December 31

Regulatory

The fourth quarter of 2024 showed a turnaround in organic net revenue. In December alone, we are now back at positive organic growth of 4.8%. With new long-term financial targets, we are now taking the next step in the company’s development, with a continued focus on profitable growth, stable returns and well-balanced debt.

Notice to extraordinary general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no 556363–2115, hereby convenes the extraordinary general meeting on 12 March 2025 at 10:00 CET at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09:30 CET. Shareholders wishing to attend the general meeting must: i)          be registered in the share register kept by Euroclear Sweden on the record…